The Next Wave: Oral GLP-1 Medications on the Horizon

Why Oral GLP-1 Medications Matter

The arrival of injectable GLP-1 receptor agonists like semaglutide and tirzepatide represented a generational leap in the treatment of obesity and type 2 diabetes. But for many patients — and the clinicians who treat them — the weekly injection requirement remains a significant barrier. Needle phobia affects an estimated 10% of adults, and self-injection anxiety contributes to delayed initiation, missed doses, and early discontinuation of GLP-1 therapy in a meaningful proportion of patients. The ability to take a GLP-1 as a once-weekly pill, rather than a subcutaneous injection, could dramatically expand the pool of patients willing and able to pursue this class of treatment.

Beyond patient preference, oral delivery offers potential advantages in terms of distribution, storage, and cost. Injectable biologic drugs require cold-chain logistics, specialized pen devices, and sharps disposal infrastructure. A small daily or weekly pill requires none of these. If oral GLP-1s can demonstrate comparable efficacy to their injectable counterparts, they could lower the barrier to prescribing in primary care settings and reach patients in parts of the world where injectable delivery is not practical. For the global obesity epidemic — which the WHO estimates affects more than 1 billion people — that is a potentially transformative development.

The commercial incentive for pharmaceutical companies is equally substantial. The global GLP-1 market was valued at over $30 billion in 2023 and is projected to more than double by the end of the decade. The first company to bring a once-weekly oral GLP-1 to market with strong efficacy and tolerability data stands to capture an enormous share of both the existing injectable market and entirely new patient segments who have been waiting for a non-injection option.

Rybelsus: The Current Oral Option

To understand where oral GLP-1s are headed, it helps to first understand where they stand today. Rybelsus (oral semaglutide 3 mg, 7 mg, and 14 mg, Novo Nordisk) is currently the only FDA-approved oral GLP-1 receptor agonist on the market. It was approved in 2019 for the treatment of type 2 diabetes and has since accumulated a robust body of evidence for glycemic control and modest weight reduction in the diabetic population.

However, Rybelsus has several meaningful limitations. It must be taken once daily — not once weekly — on an empty stomach, with no more than 4 ounces of plain water, at least 30 minutes before any food, beverage, or other medication. This rigid administration requirement is necessary because semaglutide, like most peptide drugs, is poorly absorbed through the gastrointestinal tract and relies on a specialized absorption enhancer (SNAC — sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to achieve adequate bioavailability. Even under ideal conditions, oral semaglutide achieves only about 1% bioavailability compared to injected semaglutide — meaning much higher doses are required to achieve similar plasma concentrations.

The efficacy gap between Rybelsus and injectable semaglutide (Ozempic/Wegovy) is consequential. Rybelsus at its highest approved dose of 14 mg produces roughly 4–5% body weight reduction in patients with type 2 diabetes over 26 weeks — well below the 12–15% reductions seen with subcutaneous semaglutide 2.4 mg in the STEP trials. Rybelsus is therefore not approved for weight management as a standalone indication. The next generation of oral GLP-1 formulations aims to close this efficacy gap substantially.

Novo Nordisk's Once-Weekly Oral Semaglutide (OW Oral)

Novo Nordisk is developing a once-weekly oral formulation of semaglutide (referred to internally as oral semaglutide once-weekly, or OW oral semaglutide) at doses significantly higher than Rybelsus. In Phase 2 trials, doses of 25 mg and 50 mg once weekly produced weight loss of approximately 9–17% over 68 weeks in adults with overweight or obesity — results that begin to approach the efficacy of injectable semaglutide. The Phase 3 OASIS and PIONEER PLUS programs are evaluating oral semaglutide at these higher doses for both weight management and type 2 diabetes control.

The higher doses are made possible by refinements in the SNAC delivery technology and by using a tablet with an enteric coating that optimizes absorption in a specific segment of the upper gastrointestinal tract. Early Phase 3 data released in 2023 showed promising results: the 50 mg dose produced approximately 15.1% weight reduction at 68 weeks versus 2.4% for placebo in the OASIS 1 trial, a result that was both statistically significant and clinically comparable to injectable semaglutide 2.4 mg (Wegovy). Novo Nordisk filed for regulatory approval in multiple markets in late 2023, with FDA review expected in 2024–2025.

If approved for weight management, once-weekly oral semaglutide would become a direct competitor to Wegovy on efficacy grounds, while offering the administration convenience advantage over injections. Novo Nordisk has indicated it would market the oral weight-management formulation under a separate brand name from Rybelsus, positioning it explicitly as a non-injection alternative in the growing obesity treatment market.

Eli Lilly's Orforglipron

Perhaps the most anticipated oral GLP-1 in development is orforglipron (LY3502970), a non-peptide small molecule GLP-1 receptor agonist being developed by Eli Lilly. Unlike semaglutide or tirzepatide — which are peptide molecules that require specialized delivery systems to survive the digestive tract — orforglipron is a true small molecule that is naturally orally bioavailable. It can be taken once daily without food restrictions, without absorption enhancers, and without the complex stomach-emptying timing requirements of current oral semaglutide.

Phase 2 data published in the New England Journal of Medicine in 2023 showed that orforglipron at doses of 36 mg and 45 mg produced weight loss of 14.7% and 9.4% respectively over 36 weeks in adults with obesity, compared to 2.0% for placebo. Separately, a Phase 2 trial in patients with type 2 diabetes showed dose-dependent reductions in HbA1c of up to 2.1 percentage points — results comparable to injectable GLP-1 agents. Lilly initiated the Phase 3 ATTAIN program for orforglipron in both obesity and type 2 diabetes in 2023, with results and potential regulatory filings expected by 2025–2026.

Because orforglipron is a small molecule, it may also be significantly cheaper to manufacture than peptide-based GLP-1 drugs. Lilly has noted this manufacturing advantage as a potential path to lower per-dose costs and improved global access. If Phase 3 data confirm the Phase 2 efficacy and safety profile, orforglipron could represent a fundamentally different price point for GLP-1 therapy — though final pricing decisions will ultimately depend on market and reimbursement dynamics that are difficult to predict at this stage.

Other Compounds in Development

Beyond Novo Nordisk and Eli Lilly, several other companies are advancing oral GLP-1 programs. Pfizer had been developing two oral GLP-1 small molecule candidates — danuglipron and lotiglipron — though Pfizer paused development of lotiglipron in mid-2023 citing liver enzyme elevations in a subset of patients. Danuglipron continued into Phase 2b evaluation, with Pfizer presenting early data suggesting weight loss of approximately 10% over 32 weeks at higher doses, though the program's future remains subject to ongoing clinical and safety review.

Structure Therapeutics (GPCR) is developing GSBR-1290, an oral non-peptide GLP-1 receptor agonist, with Phase 2 trials underway in both obesity and type 2 diabetes as of 2024. Carmot Therapeutics — acquired by Roche in early 2024 — had an oral GLP-1 asset (CT-996) showing early Phase 1 results. Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP receptor agonist, in both subcutaneous and oral formulations with Phase 2 results expected in 2024. The breadth of activity across companies suggests the oral GLP-1 space will likely see multiple approved agents in the coming years rather than a single winner-takes-all outcome.

Amgen's MariTide (AMG 133), a bispecific antibody that activates GLP-1 receptor signaling while blocking GIP receptor activity, represents a different approach entirely: a once-monthly or even once-every-several-months injectable option rather than a more frequent oral pill. MariTide showed exceptional Phase 2 weight loss data in 2024, and while not oral, it illustrates the diversity of delivery innovations being pursued across the industry simultaneously.

Challenges of Oral Peptide Delivery

The primary technical challenge facing oral GLP-1 development — particularly for peptide-based molecules like semaglutide — is that the gastrointestinal tract is designed to digest proteins. Peptide GLP-1 agonists face enzymatic degradation in the stomach and small intestine, as well as very poor permeability across the intestinal epithelium into systemic circulation. Overcoming these barriers requires either absorption-enhancing co-formulation (as with Rybelsus's SNAC technology), structural modifications to the peptide to resist enzymatic cleavage, or entirely bypassing the peptide paradigm through small molecule design.

Even for small molecule GLP-1 agonists like orforglipron, the challenge is achieving selectivity and safety. Small molecules often have a broader binding profile than large peptides, raising the potential for off-target interactions that could produce side effects not seen with injectable GLP-1 agents. The liver enzyme elevations seen with Pfizer's lotiglipron, and the close monitoring being applied to all oral small molecule GLP-1 programs, reflect this concern. Extensive Phase 3 safety databases will be required before any of these agents can receive regulatory approval.

Tolerability is another consideration. Gastrointestinal side effects — nausea, vomiting, diarrhea — are common across the GLP-1 class and tend to be dose-dependent. Oral formulations that achieve high peak plasma concentrations (Cmax) to compensate for lower bioavailability may produce more pronounced GI side effects than subcutaneous injections, which provide a slower, more sustained drug release profile. Formulation scientists are working to optimize the pharmacokinetic profiles of oral GLP-1s to minimize these peaks while maintaining therapeutic trough concentrations.

When Could Patients Access These Drugs?

The timeline for oral GLP-1 access varies by compound and indication. Novo Nordisk's once-weekly oral semaglutide is the furthest along for weight management, with Phase 3 data available and regulatory filings submitted in several markets as of late 2023. An FDA approval decision for the weight-management indication in the United States could reasonably come by late 2024 or 2025 if the agency does not request additional data. Rybelsus, the existing daily oral semaglutide for type 2 diabetes, already provides a proof of concept that the oral delivery approach can meet FDA standards.

Eli Lilly's orforglipron Phase 3 ATTAIN program is expected to report topline results for both obesity and type 2 diabetes in 2025, with potential regulatory submissions following thereafter. If results confirm Phase 2 efficacy and safety, U.S. approval could follow in 2026. Other compounds, including those from Structure Therapeutics, Viking Therapeutics, and Roche/Carmot, are likely one to three years behind the leading programs.

For patients currently on or considering injectable GLP-1 therapy, this pipeline development should not necessarily alter near-term treatment decisions. The injectable agents available today — Wegovy, Ozempic, Zepbound, Mounjaro — have robust clinical evidence and established safety profiles. Patients who are needle-averse or who cannot tolerate injections may wish to discuss Rybelsus as a current oral option with their prescriber, with the understanding that its efficacy for weight management is lower than the injectable alternatives. Keeping an eye on the evolving oral GLP-1 pipeline is worthwhile, but waiting for the “perfect” oral pill could mean delaying treatment that is already demonstrably effective.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. The drug development pipeline described reflects publicly available clinical and regulatory information as of early 2024. Pipeline timelines, efficacy data, and regulatory outcomes are subject to change. Always consult a qualified healthcare professional before making any treatment decisions. Product availability, indications, and insurance coverage may vary and should be confirmed with your prescriber and insurer.